Nephrology Unit, Hospital Universitario Virgen Macarena, Seville, Spain.
Infectious Diseases and Microbiology Unit, Hospital Universitario Virgen Macarena, Seville, Spain.
J Nephrol. 2023 Jan;36(1):203-212. doi: 10.1007/s40620-022-01408-8. Epub 2022 Aug 17.
Tunneled catheter-related bacteremia represents one of the major complications in patients on hemodialysis, and is associated with increased morbidity and mortality. This study aimed to evaluate the incidence of tunneled catheter-related bacteremia and, secondly, to identify possible factors involved in the first episode of bacteremia.
This is a retrospective study of all tunneled catheters inserted between 1 January, 2005 and 31 December, 2019. Data on patients with a tunneled catheter were analyzed for comorbidities, catheter characteristics, microbiological culture results and variables related to the first episode of bacteremia. Patient outcomes were also assessed.
In the 14-year period under study, 406 tunneled catheters were implanted in 325 patients. A total of 85 cases of tunneled catheter-related bacteremia were diagnosed, resulting in an incidence of 0.40 per 1000 catheter days (81.1% after 6 months of implantation). The predominant microorganisms isolated were Gram-positive organisms: Staphylococcus epidermidis (48.4%); Staphylococcus aureus (28.0%). We found no significant differences in time to catheter removal for infections or non-infection-related reasons. The jugular vein, the Palindrome® catheter, and being the first vascular access were protective factors for the first episode of bacteremia. The 30-day mortality rate from the first tunneled catheter-related bacteremia was 8.7%.
The incidence of bacteremia in our study was low and did not seem to have a relevant impact on catheter survival. S. epidermidis was the most frequently isolated microorganism, followed by S. aureus. We identified Palindrome® catheter, jugular vein, and being the first vascular access as significant protective factors against tunneled catheter-related bacteremia.
隧道式导管相关菌血症是血液透析患者的主要并发症之一,与发病率和死亡率增加有关。本研究旨在评估隧道式导管相关菌血症的发生率,并其次确定菌血症首发事件中涉及的可能因素。
这是一项对 2005 年 1 月 1 日至 2019 年 12 月 31 日期间插入的所有隧道式导管进行的回顾性研究。对患有隧道式导管的患者的合并症、导管特征、微生物培养结果以及与菌血症首发事件相关的变量进行数据分析。还评估了患者的结局。
在所研究的 14 年期间,共对 325 例患者植入了 406 个隧道式导管。共诊断出 85 例隧道式导管相关菌血症,感染发生率为每 1000 导管日 0.40 例(植入后 6 个月内为 81.1%)。分离的主要微生物为革兰氏阳性菌:表皮葡萄球菌(48.4%);金黄色葡萄球菌(28.0%)。我们未发现感染或非感染相关原因导致导管去除的时间有显著差异。颈静脉、Palindrome®导管和作为第一个血管通路是菌血症首发事件的保护因素。首次隧道式导管相关菌血症的 30 天死亡率为 8.7%。
本研究中的菌血症发生率较低,似乎对导管生存没有明显影响。表皮葡萄球菌是最常分离的微生物,其次是金黄色葡萄球菌。我们发现 Palindrome®导管、颈静脉和作为第一个血管通路是隧道式导管相关菌血症的显著保护因素。